D. J. Matthews

发表

Efficiency of signalling through cytokine receptors depends critically on receptor orientation

Robert M. Stroud, John J. Wendoloski, Scott W. Reid, 1998, Nature.

EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation

M. Gerritsen, D. J. Matthews, V. Vysotskaia, 2008, Clinical Cancer Research.

Substrate phage: selection of protease substrates by monovalent phage display.

J. Wells, D. J. Matthews, J A Wells, 1993, Science.

IL-4 and IL-13 receptors: are they one and the same?

D. J. Matthews, R. Callard, L. Hibbert, 1996, Immunology today.

Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors.

M. Boyle, L. Giebel, H. Zhan, 1997, Blood.

Engineering a soluble extracellular erythropoietin receptor (EPObp) in Pichia pastoris to eliminate microheterogeneity, and its complex with erythropoietin.

R. Stroud, B. Liu, L. Giebel, 1999, Protein engineering.

A sequential dimerization mechanism for erythropoietin receptor activation.

L. Giebel, D. J. Matthews, R. S. Topping, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Function of the interleukin-2 (IL-2) receptor gamma-chain in biologic responses of X-linked severe combined immunodeficient B cells to IL-2, IL-4, IL-13, and IL-15.

A. Minty, P. Ferrara, D. Caput, 1995, Blood.

An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment for Apc-mutation-driven intestinal tumorigenesis

S. Buczacki, P. Clark, D. J. Matthews, 2022, Science Immunology.

A survey of furin substrate specificity using substrate phage display

C. Gorman, D. J. Matthews, L. Goodman, 1994, Protein science : a publication of the Protein Society.

T1/St2-Deficient Mice Demonstrate the Importance of T1/St2 in Developing Primary T Helper Cell Type 2 Responses

D. J. Matthews, A. McKenzie, P. Fallon, 2000, The Journal of experimental medicine.

X‐SCID B cell responses to interleukin‐4 and interleukin‐13 are mediated by a receptor complex that includes the interleukin‐4 receptor α chain (p140) but not the γ chain

R. Callard, A. Minty, D. J. Matthews, 1997, European journal of immunology.

IL-13 Is a Susceptibility Factor for Leishmania major Infection

J. Blackwell, G. McKenzie, D. J. Matthews, 2000, The Journal of Immunology.

Structures of active and latent PAI-1: a possible stabilizing role for chloride ions.

D. J. Matthews, T. Stout, D. Buckley, 2000, Biochemistry.

Leishmania major IL-13 Is a Susceptibility Factor for McKenzie

J. Blackwell, G. McKenzie, D. J. Matthews, 2000 .

Regulation of human B cell growth and differentiation: lessons from the primary immunodeficiencies.

R. Callard, D. J. Matthews, S. Smith, 1997, Chemical immunology.

Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway

K. Yamaguchi, D. J. Matthews, F. Yakes, 2014, Molecular Cancer Therapeutics.

Assignment of the polymorphic intestinal mucin gene (MUC2) to chromosome 11p15

J. Attwood, S. Povey, D. Swallow, 1990, Annals of human genetics.

Current Challenges and Future Directions

M. Gerritsen, D. J. Matthews, David J. Matthews, 2010 .

Characterization of the receptor binding determinants of granulocyte colony stimulating factor

H. Zhan, D. J. Matthews, D. Young, 1997, Protein science : a publication of the Protein Society.

Pyrazolopyrimidines as dual Akt/p70S6K inhibitors.

Wei Xu, D. J. Matthews, J. Nuss, 2012, Bioorganic & Medicinal Chemistry Letters.

Biological characterization of SN 32976 , a selective inhibitor of PI 3 K and mTOR with preferential activity to PI 3 K α , in comparison to established pan PI 3 K inhibitors

K. Y. Tsang, G. Rewcastle, D. J. Matthews, 2017 .

Binding of the kunitz‐type trypsin inhibitor DE‐3 from Erythrina caffra seeds to serine proteinases: a comparative study

M Bolognesi, M. Bolognesi, P. Ascenzi, 1992, Journal of molecular recognition : JMR.

The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

K. Yamaguchi, D. J. Matthews, F. Yakes, 2015, Molecular Cancer Therapeutics.

Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo

L. Karnitz, D. J. Matthews, Y. D. Kim, 2007, Cell cycle.

Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.

Wei Xu, D. J. Matthews, J. Nuss, 2012, Bioorganic & medicinal chemistry letters.

Efficiencyofsignallingthrough cytokine receptors dependscriticallyon receptororientation

J. Wendoloski, R. Stroud, J. Finer-Moore, 2006 .

Using model-system genetics for drug-based target discovery.

D. J. Matthews, J. Kopczynski, David J. Matthews, 2001, Drug discovery today.

Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors

K. Y. Tsang, S. Gamage, W. Denny, 2017, Oncotarget.

Interfacial metal-binding site design.

D. J. Matthews, D J Matthews, 1995, Current opinion in biotechnology.

Engineering an interfacial zinc site to increase hormone-receptor affinity.

D. J. Matthews, J. Wells, 1994, Chemistry & biology.

X-SCID B cell responses to interleukin-4 and interleukin-13 are mediated by a receptor complex that includes the interleukin-4 receptor alpha chain (p140) but not the gamma c chain.

R. Callard, A. Minty, D. J. Matthews, 1997, European journal of immunology.

Biological activity of IL-4 and IL-13 on human endothelial cells: functional evidence that both cytokines act through the same receptor.

N Klein, R. Callard, D. J. Matthews, 1996, International immunology.

Abstract 3737: The PI3K/mTOR inhibitor PWT33597 regresses 786-0 renal xenografts

D. J. Matthews, Richard Ventura, A. Tai, 2012 .

Preclinical characterization of PWT33597, a dual inhibitor of PI3-kinase alpha and mTOR.

W. Denny, G. Rewcastle, D. J. Matthews, 2011 .

Transferrin and its receptor in the development of genetically determined neural tube defects in the mouse embryo

A. Copp, D. Henderson, D. J. Matthews, 1996, Developmental dynamics : an official publication of the American Association of Anatomists.

CHAPTER 14 – Substrate Phage

D. J. Matthews, 1996 .

Chapter 29. Applications of Biosensor Technology in Drug Discovery

D. J. Matthews, 1995 .

IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development.

D. J. Matthews, A. McKenzie, P. Fallon, 2000, Immunity.

Targeting Protein Kinases for Cancer Therapy

M. Gerritsen, D. J. Matthews, 2010 .

Abstract 1644: Design and discovery of PWT33597 (VDC-597), a dual inhibitor of PI3-kinase alpha and mTOR

S. Gamage, W. Denny, G. Rewcastle, 2014 .